Drug Pricing
Sun launches tildrakizumab, its star psoriasis therapy in India seven years after US FDA approval at what’s seen as a carefully calibrated price point. Can it ruffle entrenched products like secukinumab?
The Trump administration leveraged tariffs to convince the UK National Health Service to increase prices for new medicines by 25%.
Under the Inflation Reduction Act, CMS negotiated lower Medicare Part D prices for 15 drugs with 2027 costs 38%-85% lower than 2024 list prices, but analyses of net prices paid last year show smaller discounts.
The second cycle of IRA price negotiations could result in price cuts as high as 85% to the 2024 list prices, but the mean discount across the 15 negotiated drugs appears similar to the previous round.
US FDA approval of the intrathecal formulation of Zolgensma means many more patients with spinal muscular atrophy will be eligible for the gene therapy.
Redemplo is Arrowhead’s first commercial product, and the drug will enter a competitive market. Arrowhead and Ionis have taken different pricing paths, however.
Ohtuvayre is off to a great start in the US but Verona's new owner MSD has pulled the file from the EMA for the closely-watched chronic obstructive pulmonary disease drug.
The investor event will bring deal-hungry big pharma and biotech execs together but input from the FDA’s unsettled leadership will be missing this year.
Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.
Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.
Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.
Senior McKinsey executives discuss how biopharma can ace its US launch strategy and first-time launchers can stack the odds in their favor amid complex market dynamics including the MFN pricing push.
AbbVie stressed its continued revenue growth driven by Skyrizi and Rinvoq, while trying to sound unconcerned about unsettled drug-pricing policies such as MFN negotiations.
CEO Chris Boerner said talks with the Trump administration about drug pricing are ongoing, but he kept the company’s third quarter call centered on Bristol’s execution of growth plans, including closely watched new drug Cobenfy.
CEO Rob Davis said the company is continuing to negotiate with the Trump Administration on a drug pricing framework in the US.
The GLP-1 drugs Wegovy and Zepbound are cost effective at current prices, but affordability for the US healthcare system is an issue, according to ICER.
With third-quarter sales down year-on-year and quarter-on-quarter, Roche instead emphasized its performance over the first nine months of 2025, leading on the cumulative foreign exchange impact in the year to date to explain softer sales growth.
Experts at a recent summit discussed the complexities and impact of US MFN pricing from a payer perspective and emphasized the importance of a centralized purchaser of drugs to effectively negotiate prices. The potential rise of 'confidential discounts' in Germany was another key talking point.
Dupixent revenues were a record €4.16bn but the “negative buzz around vaccines” is hurting flu sales, according to chief financial officer François Roger.
Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.